Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA
- 1 March 2004
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 40 (4) , 481-486
- https://doi.org/10.1016/j.ejca.2003.10.015
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*Journal of Clinical Oncology, 2001
- Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III studyCancer Chemotherapy and Pharmacology, 2000
- Assessment of CA 15.3, CEA and TPA Concentrations during Monitoring of Breast Cancercclm, 2000
- Tumour marker measurements in the diagnosis and monitoring of breast cancerCancer Treatment Reviews, 2000
- CA 15-3 and Related Mucins as Circulating Markers in Breast CancerAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1999
- Routine tests during follow-up of patients after primary treatment for operable breast cancerAnnals of Oncology, 1995
- Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patientsBritish Journal of Cancer, 1991
- CA-15.3, TPA and MCA as markers for breast cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- The limited value of routine chest X-ray in the follow-up of stage II breast cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseasesBreast Cancer Research and Treatment, 1989